Can You Switch From Retatrutide to UBT-251 at the Same Dose?

Watch the full video on Rumble: https://rumble.com/v7g5f1w-can-you-switch-from-retatrutide-to-ubt-251-at-the-same-dose.html

Switching From Retatrutide to UBT-251: Why You Still Start at the Bottom

A couple of weeks ago, I talked about the new RETA being made by Novo Nordis called UBT-251. And the direct question that people are already asking is can you switch across the same dose you were running on RETA? Is the dosing different or do you have to titrate up again? I admittedly have not taken the time to do extensive research on UBT just because this isn't something that's readily available for me to test with.

What I can tell you is how these drugs actually work, and once you see that, the answer stops being a guess.

The whole chain matters here, so let's go through it. A triple agonist like retatrutide hits three receptors at once. GLP-1, which slows gastric emptying and drives satiety signaling in the brain. GIP, which works on insulin response and appears to blunt the nausea that GLP-1 causes on its own. And glucagon, which pushes energy expenditure and liver fat mobilization.

These are three separate levers, and each one carries its own dose response curve in your body.

So even if they do the same thing, they're targeting the same receptors, and they're technically the same drug, but different in terms of like, let's say as an example, UBT versus RETA, where there's different amounts of GLP-1, GIP, and glucagon agonists, you always want to start back down at the lowest dose and then titrate your way back up, okay? We had this conversation months and months ago for people who were transitioning from terozepatide over RETA. They're basically saying, hey, like I'm already on, you know, seven and a half milligrams of terozepatide per week.

When I move over to RETA, should I just start with that same amount? And the answer was no, but with a caveat, right? Like if you're on terozepatide and you've already been on it for six months and you want to move to RETA, you already have some, we'll say, resistance tolerance built up to the GLP-1 and the GIP agonists and terozepatide.

That tolerance is real and it is receptor specific. Your gut has adapted to a GLP-1 signal, and your nausea threshold has shifted right along with it. But none of that adaptation transfers to a receptor you have never touched.

So when you move over to RETA, you may not feel those parts of the drug if you start at the lower dose of RETA, but the part that we don't know is how you're gonna respond to the glucagon agonist.

People rarely see the glucagon side coming, and it tends to be the one that catches them off guard. It can raise resting heart rate, it can push blood glucose up in some people before the GLP-1 side pulls it back down, and it can make you feel hot and jittery in a way that tirzepatide never did.

Therefore, we need to move back down to that starting dose of RETA so that we can evaluate the way that your body responds to this new drug.

With something like UBT-251, despite the fact that, yes, it is the same in terms of GIP, GLP-1, glucagon, we still don't have that data. The ratio between those three is not published in a way I would stake a dose on, and the ratio is the entire drug. Two compounds can list the same three targets and behave nothing alike if one leans harder on glucagon than the other.

And so the safer, conservative, pragmatic approach is start at the lower dose and then work your way back up, okay? Yes, you can be a little bit more aggressive in terms of the way that you titrate, right? You can shorten that timeline, but I would definitely suggest that you are conservative in the approach and you don't just blast the UBT because once you inject this shit, like if you don't respond well to it, you get sick, there's no going back from it.